2016
Neurologic signs and symptoms frequently manifest in acute HIV infection
Hellmuth J, Fletcher JL, Valcour V, Kroon E, Ananworanich J, Intasan J, Lerdlum S, Narvid J, Pothisri M, Allen I, Krebs SJ, Slike B, Prueksakaew P, Jagodzinski LL, Puttamaswin S, Phanuphak N, Spudich S, Phanuphak P, Phanuphak N, Colby D, Chalermchai T, Chomchey N, Suttichom D, Rattanamanee S, Sangtawan P, Rattanamanee S, Nuntapinit B, Rakyat P, Inprakong S, Lucksanawong S, Ruangjan P, Nuchwong A, Kruacharoen P, O’Connell R, Adams C, Clifford K, Wendelken L, Le L, Mistry H, Tovanabutra S, Pinyakorn S, Robb M, Paul R. Neurologic signs and symptoms frequently manifest in acute HIV infection. Neurology 2016, 87: 148-154. PMID: 27287217, PMCID: PMC4940060, DOI: 10.1212/wnl.0000000000002837.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyAcute HIV infectionNeurologic findingsHIV infectionAcute HIVNeurologic manifestationsNeurologic evaluationHIV infection durationLog10 HIV RNASevere neurologic manifestationsStructural neuroimaging abnormalitiesCART initiationAntiretroviral therapyHIV RNAInflammatory markersMotor findingsNeuroimaging abnormalitiesStudy entryNeurologic signsBrain MRIInfection durationCognitive symptomsViral factorsInfectionDiagnosis
2015
Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV
Valcour VG, Spudich SS, Sailasuta N, Phanuphak N, Lerdlum S, Fletcher JL, Kroon ED, Jagodzinski LL, Allen IE, Adams CL, Prueksakaew P, Slike BM, Hellmuth JM, Kim JH, Ananworanich J, . Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV. PLOS ONE 2015, 10: e0142600. PMID: 26555069, PMCID: PMC4640512, DOI: 10.1371/journal.pone.0142600.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyStandard combination antiretroviral therapyLog10 HIV RNAAcute HIVCSF cytokinesHIV RNACentral nervous system outcomesIntegrase inhibitorsGamma-induced protein 10Duration of HIVFiebig stages IAcute HIV infectionHIV RNA levelsCNS outcomesAntiretroviral therapyInflammatory markersWeek 24Antiretroviral treatmentHIV infectionPlasma neopterinRandomized armProspective evaluationMean ageHealthy controlsCCR5 antagonists